Pricing & Access· September 10, 2026 · 23 min read
Topic
Payer Criteria
Clinical documentation, diagnosis, prior therapy, lab, severity, and renewal rules embedded in payer policies.
Approvals· September 5, 2026 · 29 min read
Etcamah's Sept 4 Approval Does Not Rewrite Orserdu PAs or ODAC's ctDNA Dispute
Approvals· September 4, 2026 · 36 min read
Lirafugratinib's Sept 27 PDUFA Does Not Rewrite Pemazyre PAs or Lytgobi CDx
By Ran Chen#PDUFA Date#FDA Approval#NDA Approval
Approvals· September 3, 2026 · 34 min read
Injectafer's Phosphate Boxed Warning Does Not Rewrite J1439, AP Generics, or Oral-Iron PAs
By Ran Chen#Boxed Warning#Label Warnings#FDA Approval
Approvals· September 2, 2026 · 33 min read
Aqneursa's Sept 19 A-T PDUFA Does Not Rewrite NPC-Only PAs or the 15 kg Floor
By Ran Chen#PDUFA Date#FDA Approval#NDA Approval
Approvals· September 1, 2026 · 29 min read
Camzyos's Sept 30 Adolescent PDUFA Does Not Rewrite Adult REMS or Age-18 PA Gates
By Ran Chen#PDUFA Date#FDA Approval#NDA Approval
Pricing & Access· July 15, 2026 · 21 min read
COPD Access Landscape 2026: Inhaled Triple Therapy, Dupilumab, and Ensifentrine
Pricing & Access· July 15, 2026 · 18 min read
Heart Failure Access Landscape 2026: GDMT, Entresto Generic, Kerendia, and Verquvo
By Ran Chen#Heart Failure#Payer Criteria#Cardiovascular
Pricing & Access· July 15, 2026 · 19 min read
IPF Access Landscape 2026: Jascayd, Ofev Generic entry, and Pirfenidone Pricing
Pricing & Access· July 13, 2026 · 20 min read
ATTR-CM Access Landscape: Tafamidis, Acoramidis, and Vutrisiran
By Ran Chen#Rare Disease#Payer Coverage#Payer Criteria